AZD5438 in Patients With Advanced Solid Malignancies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

NCT01112397

Solid Malignancies

TERMINATED PHASE1

AZD1152 in Patients With Advanced Solid Malignancies

NCT00338182

Tumors

COMPLETED PHASE1

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

NCT02579226

Advanced Solid Tumours

COMPLETED PHASE1

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

NCT00389389

Neoplasms

COMPLETED PHASE1

AZD8330 First Time in Man in Patients With Advanced Malignancies

NCT00454090

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD5438

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced solid malignancy
* Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria

* Radiotherapy within 3 weeks of the start of treatment
* Investigational product within the last 3 weeks
* Systemic cytotoxic anti-cancer therapy within the last 3 weeks
* Any significant clinical disorder that makes it undesirable for the patient to participate

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No